Merck reports positive phase III results for sac-TMT and neoantigen therapy
According to TradingView, Merck reported positive phase III results for sac-TMT in endometrial cancer and individualized neoantigen therapy in melanoma.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Merck has posted positive results from phase III trials. The TroFuse-005 study showed meaningful improvements in progression-free survival, overall survival and response rate for sac-TMT in patients with advanced or recurrent endometrial cancer.
The INTerpath-001 trial also succeeded, with individualized neoantigen therapy producing positive results in melanoma. Phase III studies for MK-2010 are expected to begin in the first half of 2027.
why it matters
For Merck, this is an important step in its oncology pipeline, as successful phase III readouts raise the chances of regulatory approval for new drugs and strengthen the company's long-term prospects. For the broader market, the effect is limited to one large company and the pharma sector rather than wide indices.
market impact
Merck shares and pharma sector: successful trials support the company's pipeline outlook.
tags
instruments
sources
- MRK: Positive phase III results advance sac-TMT and personalized neoantigen therapy — TradingView, 26 October 2026 at 22:12 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗